#32. AI Drug Discovery Startups

In this episode, we explore how artificial intelligence (AI) is revolutionizing drug discovery by reducing costs and accelerating timelines through deep learning, generative models, and knowledge graphs. We trace the journey from early 2010s pioneers to today’s hybrid models that integrate software and drug assets, spotlighting leading companies like Recursion, Exscientia, and Insilico Medicine. The episode examines how success is now measured by clinical trial results and unpacks the high-stakes global competition between the United States and China to dominate this field. While the initial investment surge has stabilized, major pharmaceutical firms continue to drive progress through AI-driven partnerships, shaping the future of healthcare innovation. Produced by Dr. Jake Chen.